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Abstract Since the Edmonton trials, insulin independence
can reproducibly be achieved after islet transplantation.
However, a majority of patients resume insulin treatment in
the first 5 years after transplantation. Several mechanisms
have been proposed but are difficult to pinpoint in one
particular patient. Current tools for the metabolic monitor-
ing of islet grafts indicate islet dysfunction when it is too
late to take action. Noninvasive imaging of transplanted
islets could be used to study β-cell mass and β-cell
function just after infusion, during vascularization or
autoimmune and alloimmune attacks. This review will
focus on the most recent advances in various imaging
techniques (bioluminescence imaging, fluorescence optical
imaging, MRI, and positron emission tomography). Em-
phasis will be placed on pertinent approaches for translation
to human practice.
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Introduction
Within the past decade, islet transplantation has become one
of the most effective approaches, after pancreas transplan-
tation, to treat type 1 diabetes. This is largely the results of
the impact of the landmark “Edmonton protocol” that
allowed consistent achievement of insulin independence,
mainly by transplanting a high islet mass to offset the poor
engraftment rate [1]. Low islet engraftment is thought to be
the result of islet damage caused by the isolation procedure,
ischemia-reperfusion injury, and nonspecific inflammatory
processes such as an instant blood-mediated inflammatory
reaction [2].
The excellent results of the Edmonton protocol at 1 year
have been dampened by the 5-year outcomes reporting
insulin independence persistence in only 10% to 15% of
patients, although graft function was retained (positive C-
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peptide) in most of the recipients [3]. Proposed mechanisms
for long-term islet graft loss are allogeneic immune
response, recurrence of autoimmunity, immunosuppressive
drug toxicity, lack of β-cell regeneration, or exhaustion of
the islet graft [4–8].
Compared with other organ transplants, the mechanisms
of islet engraftment and islet loss are poorly understood.
This is a result of the lack of monitoring tools able to allow
early detection of graft damage. Classically used metabolic
parameters (glycemia, basal and stimulated C-peptide
levels, or arginine-stimulated insulin levels) are late
markers of islet graft dysfunction and do not provide an
idea of the islet loss mechanisms [9]. Current routine
immune monitoring is based on the assessment of alloim-
mune [10] and autoimmune antibodies [11] reflecting only
humoral immunity. Moreover, whereas the importance of
anti-HLA antibodies is emerging as a factor of islet graft
loss [12], the significance of autoantibodies is unclear, as
their correlation with clinical outcomes is not well
documented [6]. Cellular immunity monitoring appears to
be of greater interest, but cell-based assays are more
difficult to set up and are currently under experimental
investigation [13]. After intraportal infusion, liver biopsy
shows islet tissue in only 31% of cases without relevant
mononuclear cell infiltration, even in the case of ongoing
islet loss [14].
Similar considerations apply to preclinical type 1
diabetes. Although remarkable advances have been made
in the recent years in understanding the pathogenesis of
type 1 diabetes, clinical tools to monitor islet mass in
humans are still lacking.
In this context, direct visualization of native and
transplanted islets has broadened the scope of diabetes
research. Because of small islet size (50–300 μm) and
large distribution area in the pancreas or the liver,
noninvasive islet imaging is very challenging. In islet
transplantation, the ideal imaging technique should have
high resolution to be able to detect single islets in the
liver, giving an islet- or β-cell–specific signal that would
be easily and accurately quantified, and of course,
correlated to islet functionality and islet transplantation
outcome. Moreover, to allow graft rescue in the case of
allograft rejection, the decrease of signal must be
observed earlier than the alteration of the usual graft
function parameters. Finally, to be translated to human
clinical practice, safety must be demonstrated both for
the recipients and the islet graft. Since the last review on
this topic in Current Diabetes Reports published in 2007
[15], some progress has been made thanks to modern
diagnostic equipment, providing an ever-growing sensi-
tivity. This review will summarize the major recent results
in the development of noninvasive in vivo islet imaging
techniques in the field of islet transplantation (Table 1).
Optical Imaging
In vivo optical imaging uses light as a source of contrast. In
the field of islet transplantation, the use of bioluminescence
and fluorescence optical imaging has been reported for the
study of islet transplants in mice. However, due to low
penetration depth of the light signal, this method is not
about to be applicable to human studies.
Bioluminescence Imaging
Bioluminescent cells are modified to express the luciferase
enzyme gene, either after in vitro islet transfection with a
viral vector [16], or by generating transgenic mouse strains
expressing the luciferase gene under the regulation of the
insulin promoter (FVB-RIT-Luc and FVB-MIT-Luc mice)
[17•, 18]. For imaging, the luciferase substrate, injected just
before image acquisition, is oxidized by luciferase in
luciferase-expressing cells, in an oxygen- and ATP-
dependent manner. The product of the reaction emits light
that can be detected and quantified in vivo. However, as
light attenuates very strongly when it propagates through
the tissue before reaching the detector (0.5 cm), biolumi-
nescence imaging (BLI) can only be used in mice.
The Vanderbilt University group has recently shown that
the BLI signal from MIT-Luc mice was very well correlated
with the number of syngeneic islets in vitro and in vivo
after transplantation under the kidney capsule. However, the
correlation was lower when islets were transplanted in the
liver, probably because of higher light attenuation, sparse
islet distribution throughout the liver, and perhaps higher
islet loss after intraportal infusion [19]. Chen et al. [17•]
reported that after allogeneic islet transplantation in
streptozotocin (STZ)-induced diabetic mice, BLI intensity
began to show a progressive decrease approximately 5 days
before the rise of hyperglycemia. One day before the
diagnosis of rejection based on hyperglycemia, signal was
decreased by 67%. Anti-lymphocyte serum (ALS), injected
when a decrease in BLI signal of more than 30% was
observed, allowed the islet graft to be saved in 60% of
cases, compared with 0% when ALS was given after a 20%
glycemic rise. In the failed transplants that were not
salvaged by ALS therapy, rejection occurred 53.5 days
after transplantation, compared with 22.1 days when
rejection diagnosis was based on glycemia.
Despite these interesting results, some issues remain to
be addressed. In the transgenic mouse models, biolumines-
cence measurements can be influenced by extracellular
glucose: light emission from isolated islets cultured
overnight in high glucose concentrations was greater in
vitro, but neither isolated islets nor animals acutely exposed
to high glucose (intraperitoneal glucose tolerance test) have
increased BLI emission [19]. However, following STZ
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treatment, the decline in BLI was less than the decrease in
β-cell mass assessed by histology (78% vs 96%). In these
models, luciferase expression is under control of the insulin
promoter fragment and can be influenced by the glucose
level, particularly in the setting of chronic hyperglycemia.
Another issue is that despite the possibility of three-
dimensional reconstruction to precisely define the location
of the bioluminescence source [19], the resolution of the
signal is low and does not allow detection of single islets
scattered throughout the liver. BLI can be a useful research
tool in islet transplantation in the mouse model and is more
accurate for subcapsular islet grafts. The influence of
glycemia needs to be clarified in the MITand RIT transgenic
mice.
Fluorescence Imaging
Evgenov et al. [20] described another application of optical
imaging to human islet transplantation in mice using a near
infrared fluorescent dye combined with dextran-coated
superparamagnetic nanoparticles. Islets were labeled by
overnight incubation and grafted under the kidney capsule
of immunodeficient mice. The signal could be detected in
vivo and confirmed by histologic analysis as the fluorescence
remained visible on confocal fluorescence microscopy after
tissue fixation. Additionally, contrary to BLI, no substrate
injection was required before imaging.
Fluorescence imaging has also been used in vivo to
visualize islets transplanted into the anterior chamber of the
Table 1 Summary of transplanted islet imaging techniques
Imaging technique Application domain Advantages Disadvantages
BLI Research tool in mice Very sensitive Low spatial resolution
Correlated to the
functional mass
Possible interaction with glycemia
Less accurate in the intraportal
model
MRI No radiation Low sensitivity
Good spatial resolution
SPIO-labeled islets All animal models Feasibility in humans Pretransplantation labeling
Described in humans Quantification Long-term labeling persistence in
intraportal transplantation unclear
Correlated to the islet mass Correlation with islet function
less demonstrated
Gadolinium-labeled
islets
Described in mice Feasibility in the
intraportal model
Pretransplant labeling
Could be used in humans Nonpersistence of the labeling
agent after 60 days
Encapsulated islets Described in mice and swine Better sensitivity No correlation with the
islet functionNo use in humans No or less immunosuppressive
drugs
Manganese enhanced Described in mice No pretransplant labeling Use for native pancreas imaging
Used in humans for
liver disease
Correlated to the islet
functional mass
Not accurate for intraportal
transplantation
Islet vascularization
imaging
Described in mice Potentially a good surrogate
marker for early graft function
Requires high-field MRI
Difficult to translate
in humans
Difficult to quantify in the
intraportal model
PET imaging High sensitivity Islet and recipient irradiation
Low spatial resolution
[18F] FDG Described in rats
and humans
Imaging just after
islet infusion
Pretransplant labeling
Short half-life
Noninvasive reporter
probe imaging
Described in mice Imaging of islet functionality Pretransplant islet transfection
Not directly applicable
to humans
Time limited technique
Gut uptake
GLP-1 receptor
PET imaging
Used in animal models Imaging of endocrine pancreas Islet specificity and sensibility in
intraportal transplantation unclearUsed in humans Potentially applicable to
intraportal liver transplant
BLI bioluminescence imaging; [18 F]FDG 18 F-fluorodeoxyglucose; GLP-1 glucagon-like peptide-1; PET positron emission tomography; SPIO
superparamagnetic iron oxide
Curr Diab Rep (2011) 11:375–383 377
eye by using the cornea as a natural body window. Speier et
al. [21] transplanted islets from transgenic mice expressing
enhanced green fluorescent protein under control of the rat
insulin-1 promoter (RIP-GFP). By using intraocular and
intravenous injections of fluorescent dyes, they were able to
study islet engraftment and revascularization, β-cell func-
tionality (calcium handling), and β-cell death. Recently,
Perez et al. [22] transplanted unlabeled allogeneic islets in
the anterior chamber of a baboon. Islets were implanted in
the iris and could be observed using slit-lamp examination.
Fluorescein angiography of the anterior chamber revealed
islet revascularization. In this preclinical study, no severe
ocular adverse effects were reported, but only 20,000 islet
equivalents were transplanted.
Magnetic Resonance Imaging
In the field of islet transplantation, MRI is of growing
interest. Its high spatial resolution and penetration depth,
and lack of ionizing radiation make studies directly
translational to humans. But because MRI cannot naturally
distinguish the transplanted islets from the surrounding
liver tissue, the addition of a contrast agent is required.
Superparamagnetic Iron Oxide Nanoparticles
In 2004, Jirak et al. [23] were the first to show that
transplanted islets could be detected in the liver of rat with
a dedicated rodent 4.7T MR system. Islets were labeled in
vitro before transplantation using superparamagnetic iron
oxide (SPIO) nanoparticles (ferucarbotran; Resovist®,
Schering AG, Berlin, Germany) at a concentration of
137.5 μg Fe/mL. SPIO nanoparticles are commercially
available contrast agents used for the detection of liver
lesions. Their shortening effect on the T2 relaxation time of
surrounding protons gives a strong hypointense signal on
T2-weighted images (Fig. 1). Ferucarbotran and ferumoxide
(Endorem®, Guerbet, Villepinte, France; or Feridex®,
AMAG Pharmaceuticals, Lexington, MA) are the two
clinical-grade carboxydextran- or dextran-coated SPIO nano-
particles tested as islet transplant labeling agents.
SPIO Labeling Studies
After in vitro incubation with islets, SPIO nanoparticles can
be detected by electronic microscopy in the lysosomes of β
cells, but also in other islet cells (α cells, δ cells, and islet
macrophages), and also in the interstitial spaces around the
islet cells [24–27]. The accumulation of SPIO nanoparticles
in islets seems to depend on the iron and cell concentration
in the culture medium and the incubation time [23]. As
shown by Evgenov et al. [26], iron distribution within islet
cells is not uniform, ranging from 10% to 70%. Recent
studies tried to improve efficacy of islet labeling by using
liposomes or polyethyleneimine [28, 29]. It was shown that
isolated human and rodent islets can be labeled with SPIO
nanoparticles without impairing their insulin-secreting
capacity or viability [24, 25, 27].
Evgenov et al. [30] showed that the iron load, charac-
terized by a short T2 relaxation time, was higher in pure
islets compared with exocrine tissue alone. However,
labeling exocrine tissue reduced its T2 relaxation time,
suggesting that exocrine tissue can also be labeled by SPIO
nanoparticles. However, even if exocrine tissue was slightly
labeled, no signal difference coming from the islet graft was
observed 2 days after intraportal transplantations of a same
islet number of different purity (98% and 50%) in
immunocompromised nonobese diabetic (NOD)–scid mice.
Higher rates of apoptosis and graft macrophage infiltration
in the 50% purity transplants argued for a rapid clearance of
exocrine cells without MRI signal difference after day 2.
However, in that article, when low (20%) and high purity
preparations were incubated with the same number of islets,
the iron-to-protein ratio was lower in the low purity
preparation, probably reflecting higher cell concentration
in the culture medium with a lower islet iron uptake.
Signal Quantification
In earlier studies, the quantification of SPIO-labeled islets
in rodent liver was made manually by counting the number
of hypointense spots in 8 to 13 slices, with a slice thickness
varying from 0.5 to 2 mm [27, 30]. This quantification
method showed an excellent correlation with the number of
transplanted islet equivalents in the liver of NOD-scid mice
(from 200 to 1,000), with approximately three or four islets
clusters visualized for 10 transplanted. However, in a
clinical application perspective, manual counting is very
Fig. 1 3T MRI of ferucarbotran-labeled islet transplanted in the liver
of a rat (T2*-weighted gradient echo sequences) (Berney, Personal
data)
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difficult in human examinations because of higher volume
of the liver with higher number of islets. In a pilot study in
humans, Saudek et al. [31•] used manual counting on 72
slices covering the whole liver. Recently, Medarova et al.
[32] developed, for non-human primates, a semiautomated
image segmentation method. A region of interest was
drawn manually around the liver, then, based on T2* value,
an automated algorithm was applied to segment the liver
between liver parenchyma and islets clusters [32]. We
recently developed a novel quantification method using the
difference of two simultaneously acquired MRI images
(three-dimensional ultra-short echo time) giving a positive
contrast from the SPIO-labeled islet with suppression of the
liver background and vessels, than can be confused with
hypointense islets clusters with classical T2* sequences. An
intensity threshold applied within the liver provides a
number of enhanced pixels, referring to the number, but
also to the size of the islet signal. Excellent correlation
between signal intensity and number of transplanted islets
was obtained [33•].
In Vivo Studies in Syngeneic Transplantation
With human Feridex-labeled islets, Evgenov et al. [26]
showed that in immunodeficient mice, the number of islets
decreased gradually during the first 2 weeks (−40%),
suggesting a significant loss after islet injection, confirmed
by graft TUNEL (Terminal deoxynucleotidyl transferase
dUTP nick end labeling) analysis showing high rates of
apoptosis during the first days after transplantation. In the
syngeneic primate model, the same team observed a 25%
drop in transplanted islet mass between days 3 and 8,
followed by stabilization of the graft up to day 30 [32]. In
the rat model with Resovist-labeled islets by Kriz et al.
[27], the MRI signal in the syngeneic group was unchanged
between weeks 1 and 6, but in their pilot study in humans, a
45% signal loss was reported in 4 patients, 1 week after islet
transplantation [31•]. In that study, the purity of the islet
preparation was not reported and the first MRI was done
1 day after transplantation. It is probable that the loss of the
signal was due in part to the loss of islet cells, but also to the
loss of labeled exocrine cells between day 1 and week 1.
Long-term studies to assess the permanence of the signal in
syngeneic intraportal islet transplantation models are lacking.
Studies in Immune Rejection
SPIO nanoparticles have been studied in immune rejection
models. Evgenov et al. [26] showed that the signal
generated by Feridex-labeled human islets decreased faster
and to a higher extent in immunocompetent mice than in
NOD-scid mice, especially after 10 days, with increasing
numbers of apoptotic cells seen in the graft. In this work,
histologic analysis showed that iron was detected in islet
cells and not in infiltrating cells. At the time of islet-cell
death, the iron was found in Kupffer cells, known for
clearing rapidly free iron particles. Using Resovist in the
allogeneic diabetic rat model, the Prague team also
observed a 50% signal reduction at 2 weeks compared
with the initial image at 1 week, contemporaneous with
graft mononuclear cell infiltration [27]. In this study, based
on glycemia, islet function was lost in all rats by day 12.
Studies in Humans
Two pilot studies reported MRI imaging of Resovist-labeled
transplanted islets in patients with type 1 diabetes. With 1.5-T
MRI imaging in four patients with type 1 diabetes, we were
able to identify iron-labeled islets as hypointense spots within
the liver [34]. Notably, all patients became insulin-
independent, confirming the absence of islet cell toxicity by
SPIO labeling. One participant had evidence of spontaneous
liver iron overload (hemosiderosis), preventing islet visuali-
zation. A diffuse hypointense signal was observed in another
patient after he had received intravenous iron therapy. At 3T,
Saudek et al. [31•] could also visualize SPIO-labeled islets in
the liver of seven patients from a group of eight. In four
patients, the signal has been followed during 24 weeks and
showed an important decrease of 45% in the first week
followed by a much slower decline in the following weeks
with a positive C-peptide measurement. However, the number
of detected islets was still low taking into account the total
number of infused islets, without obvious correlation between
the number of visualized and transplanted islets.
Currently, studies on SPIO nanoparticles in islet trans-
plantation have shown that islets can be labeled and
visualized with clinical-grade MRI without toxicity and
can be quantified by semiautomated analysis. Although
signal persistence for more than 4 months was reported
[25], the long-term stability of staining has not been fully
explored in syngeneic models and the usefulness of this
technique in the diagnosis and treatment of immune
rejection has not yet been demonstrated. New SPIO
nanoparticles are under development [35].
Ferromagnetic Iron Oxide Nanocubes
Recently, Lee et al. [36•] developed ferromagnetic iron
oxide nanocubes (FIONs) that are polyethylene glycol-
phospholipid–encapsulated magnetite nanoparticles of
58 nm. These nanocubes have shorter T2 relaxation time
compared with Feridex and can label islets after overnight
incubation without toxicity. FION-labeled islets could be
observed as hypointense spots in the liver of syngeneic rat
up to 150 days, whereas allogeneic islets disappeared
within 15 days.
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Gadolinium-Labeled Islets
Biancone et al. [37] used gadolinium-HPDO3A as an islet-
labeling agent, providing islet hyperintense signal in a T1-
weighted sequence. Although isolated islets could be seen
in the liver of SCID mice, labeling did not persist beyond
60 days.
Islet Encapsulation Imaging
Islet encapsulation has been shown to protect islets against
alloimmune rejection. Barnet et al. [38] added labeling
agents inside the islet capsule. They first used a magneto-
capsule (encapsulation of human islet and Feridex), trans-
planted intraportally in a swine model [38]. They showed
that the hypointense signal could be easily detected in the
swine liver at 3 weeks with significant human C-peptide
levels. In a recent study, the same group used a fluorocapsule
composed of encapsulated islets with perfluorocarbon, which
can be detected under the swine kidney capsule using
fluorine-19 MRI, but also ultrasonography and CT imaging
[39•]. However, with these techniques, islet viability and
functionality cannot be correlated to the signal because the
capsule can be detected whether or not the islets are alive.
Manganese-Enhanced MRI
All these techniques require in vitro labeling before
transplantation and, therefore, the correlation between the
islet mass and the functionality depends on the duration of
label retention by the islets and rapid clearance after islet
loss. Another way would be to enhance islets with a
contrast agent injected during imaging that would reflect
islet mass and islet functionality. In this view, manganese
(Mn), a T1 contrast agent, represents a very interesting
option, because in β cells, Mn2+ mimics Ca2+ influx
preceding insulin secretion in response to hyperglycemia.
Mn-enhanced MRI has shown that the signal coming from
native pancreas of nondiabetic mice was increased by 51%
after intravenous glucose load compared with saline load
[40]. This increase was not observed in high-dose STZ
mice and was only 20% in low-dose STZ mice. Mn-
enhanced MRI seems to be a promising approach to evaluate
β-cell functional mass in native pancreas. However, this
technique might be difficult to apply to liver islet transplan-
tation due to high Mn liver uptake and little signal coming
from diffusely scattered islets.
Islet Vascularization MRI
MRI has also been tested to study islet vascularization.
Hathout et al. [41] described dynamic contrast-enhanced
imaging (DCE-MRI) to evaluate islet neovascularization
after intravenous injection of gadolinium–diethylenetriamine-
penta-acetic acid. The rate of diffusion from the vasculature to
interstitial spaces depends on microvessel surface area,
permeability, and blood flow. Using a 11.7T rodent MRI
studying mice after intraportal syngeneic islet transplantation,
they showed a trend toward enhancement of the signal in the
right liver lobe, which had received the islet transplantation,
compared with the median and left lobes [42]. This was
observed at day 7 but not at day 3, with a good correlation
between the signal enhancement and neovascular density
determined by von Willebrand factor immunohistochemical
analysis. Using this technique in a marginal mass model with
diabetic mice, the same authors found a negative correlation
between the signal enhancement and the glycemia at day 14
[43]. However, this method has been described with high
field rodent MRI in a selective intraportal transplantation
model allowing comparison between grafted and ungrafted
liver lobes to see the islet-based contrast enhancement.
Moreover, the DCE sequence is done on a single slice and
does not cover the whole liver, with a total acquisition time
of 32 min, making human clinical application as yet
unpractical. However, alterations in the microvasculature
may reflect leukocyte infiltration and inflammation, as
demonstrated in MRI analysis of NOD mice pancreas [44].
Positron Emission Tomography Imaging
Positron emission tomography (PET) is a noninvasive
functional imaging technique that provides high resolution,
good sensitivity, and accurate quantification of physiologic,
biochemical, and pharmacologic processes in living subjects.
This technique depends strongly on the choice of the
radioactive probes.
18F-Fluorodeoxyglucose
Earlier studies in islet transplantation used the classic tracer
18F-fluorodeoxyglucose ([18F]FDG), a glucose analogue
that can be taken up by β cells. However, because the liver
uptake is very high, this tracer cannot discriminate islets in
the liver if injected intravenously before imaging. Our group
was the first to use this marker by incubating in vitro the islets
before intraportal transplantation in a rat model [45]. Using
this technique in humans by labeling 23% of the transplanted
islets, Eriksson et al. [46•], showed that the radioactivity peak
occurred 19 min after infusion was 75% of what was injected,
illustrating the early loss that occurs during the transplanta-
tion procedure [46•]. Distribution in the liver was heteroge-
neous with wide variation of concentration and location.
However, because of the short half-life of 18F (110 min), this
technique can be used only to study islet survival and
engraftment immediately after islet infusion.
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Noninvasive Reporter Gene Probes Imaging
With this technique, a cell is transfected with a reporter
gene to produce a specific protein that can be detected by
the administration of a reporter gene probe. In 2006, two
groups transfected human islets with adenovirus to express
the herpes virus simplex 1 thymidine kinase (HSV1-TK)
[47, 48]. After transplantation in a mouse model, [18F]
FHBG, a substrate of HSV1-TK, was administrated to
quantify its retention in islets by microPET imaging. After
axillar or subcapsular transplantation, the number of
injected islets correlated well with the PET signal. But
for intraportal transplantation, as the probe was cleared
through the intestine and kidney, it gave spillover
background signal in the liver of small animals. However,
after transplantation, the correlation with islet number was
good [48]. The main issue was that the PETsignal returned
to baseline after 30 days because of regression of
expression of the reporter gene. By using a lentivirus
vector, Lu et al. [49] prolonged graft monitoring up to
90 days. However, these techniques require pretransplant
gene modifications possibly damaging islet cells, with
limited direct human clinical applications.
Glucagon-like Peptide-1 Receptor PET Imaging
Because the glucagon-like peptide-1 (GLP-1) receptor is
highly expressed in islets, GLP-1 receptor ligand could be
an ideal probe for PET imaging of islets. Recent studies
showed that labeled exendin holds great potential for
noninvasive imaging of β cells in the native pancreas
[50••] and can be useful in humans for detection of
pancreatic insulinoma [51, 52•]. In the latter study, [111In]
DOTA-exendin-4 successfully detected insulinoma in all six
patients, with high kidney uptake, but very low liver
background, suggesting potential application for intraportal
islet transplantation. With this technique, Pattou et al. [53]
recently reported successful imaging of a functioning islet
autograft in the forearm muscle of the recipient.
The Quest for In Situ β-Cell Labeling
The development of PET or single photon emission
computed tomography probes able to label β cells in situ
after systemic administration is a favored research area.
They would provide a method that can be repeated over
time to visualize islet grafts, but could also be useful to
monitor islet mass within the pancreas in type 1 diabetes
[54]. The main problem of this approach is the specificity
and affinity of the marker used to label islet cells. Studies
performed by Sweet et al. [55] calculated that the specific
affinity for a cell-labeling agent should be over 1,000 times
higher than that for the surrounding tissue for the imaging
of islets within the pancreas; this figure rises to 5,000 for
islets transplanted into the liver. Although the [111In]
DOTA-exendin-4 probe, developed for insulinoma imaging,
was able to faintly image intramuscular islet autografts
[46•], affinity issues have not yet rendered in situ labeling
applicable for intraportally transplanted islets.
Conclusions
Although in vivo imaging of transplanted islets is a rapidly
developing field, correct evaluation of transplant β-cell
functional mass remains a problem. The majority of studies
highlighted in this review used an islet labeling agent
before transplantation, with some issues. First, in vitro
preinfusion manipulation is required, potentially altering
islet functionality. Second, long-term persistence of the
labeling in functioning islets is difficult to obtain. Third, the
detected signal does not reflect directly the islet function,
potentially inducing false-positive results. Relevant methods
showing promise in animal models are difficult to translate to
clinical practice: imaging of islet transplant under the kidney
capsule is totally different from imaging islets scattered
throughout a whole human liver, and high-field-strength
systems used in rodents have higher spatial resolution than
low-field-strength clinical-grade systems.
The development of safe and specific tracers of islet
graft function and mass is an important objective for further
studies. Multimodal imaging techniques such as combined
PET and MRI may be promising tools for clinical islet
transplantation research with high spatial resolution and
sensitivity. However, the low availability of such imaging
methods make them as yet difficult to use as routine and
systematic monitoring for islet transplant recipients.
Acknowledgments C. Toso was supported by the Swiss National
Science Foundation (SCORE grant 3232230–126233). T. Berney was
supported by the Swiss National Science Foundation (grant 320030-
127583/1) and Insuleman.
Disclosure No potential conflicts of interest relevant to this article
were reported.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven
patients with type 1 diabetes mellitus using a glucocorticoid-free
immunosuppressive regimen. N Engl J Med. 2000;343(4):230–8.
Curr Diab Rep (2011) 11:375–383 381
2. Barshes NR, Wyllie S, Goss JA. Inflammation-mediated dysfunc-
tion and apoptosis in pancreatic islet transplantation: implications
for intrahepatic grafts. J Leukoc Biol. 2005;77(5):587–97.
3. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after
clinical islet transplantation. Diabetes. 2005;54(7):2060–9.
4. Roelen DL, Huurman VA, Hilbrands R, et al. Relevance of
cytotoxic alloreactivity under different immunosuppressive regimens
in clinical islet cell transplantation. Clin Exp Immunol. 2009;156
(1):141–8.
5. Huurman VA, Velthuis JH, Hilbrands R, et al. Allograft-specific
cytokine profiles associate with clinical outcome after islet cell
transplantation. Am J Transplant. 2009;9(2):382–8.
6. Huurman VA, Hilbrands R, Pinkse GG, et al. Cellular islet
autoimmunity associates with clinical outcome of islet cell
transplantation. PLoS One. 2008;3(6):e2435.
7. Bellin MD, Sutherland DE, Beilman GJ, et al. Similar islet
function in islet allotransplant and autotransplant recipients,
despite lower islet mass in autotransplants. Transplantation.
2011;91(3):367–72.
8. Niclauss N, Bosco D, Morel P, et al. Rapamycin impairs
proliferation of transplanted islet beta cells. Transplantation.
2011;91(7):714–22.
9. Berney T, Toso C. Monitoring of the islet graft. Diabetes Metab.
2006;32(5 Pt 2):503–12.
10. Ferrari-Lacraz S, Berney T, Morel P, et al. Low risk of anti-human
leukocyte antigen antibody sensitization after combined kidney
and islet transplantation. Transplantation. 2008;86(2):357–9.
11. Bosi E, Braghi S, Maffi P, et al. Autoantibody response to islet
transplantation in type 1 diabetes. Diabetes. 2001;50(11):2464–71.
12. Kessler L, Parissiadis A, Bayle F, et al. Evidence for humoral
rejection of a pancreatic islet graft and rescue with rituximab and
IV immunoglobulin therapy. Am J Transplant. 2009;9(8):1961–6.
13. Lacotte S, Berney T, Shapiro AJ, Toso C. Immune monitoring of
pancreatic islet graft: towards a better understanding, detection
and treatment of harmful events. Expert Opin Biol Ther. 2011;11
(1):55–66.
14. Toso C, Isse K, Demetris AJ, et al. Histologic graft assessment after
clinical islet transplantation. Transplantation. 2009;88(11):1286–93.
15. Gaglia JL. Noninvasive imaging of islet transplantation and
rejection. Curr Diab Rep. 2007;7(4):309–13.
16. Fowler M, Virostko J, Chen Z, et al. Assessment of pancreatic
islet mass after islet transplantation using in vivo bioluminescence
imaging. Transplantation. 2005;79(7):768–76.
17. • Chen X, X Zhang, C Larson, et al. Prolonging islet allograft
survival using in vivo bioluminescence imaging to guide timing of
antilymphocyte serum treatment of rejection. Transplantation.
2008;85(9):1246–52. This paper demonstrates that allogeneic
islet grafts can be salvaged by ALS injection when rejection
diagnosis was based on bioluminescence signal before rise in
glycemia.
18. Park SY, Wang X, Chen Z, et al. Optical imaging of pancreatic
beta cells in living mice expressing a mouse insulin I promoter-
firefly luciferase transgene. Genesis. 2005;43(2):80–6.
19. Virostko J, Radhika A, Poffenberger G, et al. Bioluminescence
imaging in mouse models quantifies beta cell mass in the pancreas
and after islet transplantation. Mol Imaging Biol. 2010;12(1):42–53.
20. Evgenov NV, Medarova Z, Dai G, et al. In vivo imaging of islet
transplantation. Nat Med. 2006;12(1):144–8.
21. Speier S, Nyqvist D, Cabrera O, et al. Noninvasive in vivo imaging
of pancreatic islet cell biology. Nat Med. 2008;14(5):574–8.
22. Perez VL, A Caicedo, DM Berman, et al. The anterior chamber of
the eye as a clinical transplantation site for the treatment of
diabetes: a study in a baboon model of diabetes. Diabetologia. 54
(5):1121–26.
23. Jirak D, Kriz J, Herynek V, et al. MRI of transplanted pancreatic
islets. Magn Reson Med. 2004;52(6):1228–33.
24. Ris F, Lepetit-Coiffe M, Meda P, et al. Assessment of human islet
labeling with clinical grade iron nanoparticles prior to transplantation
for graft monitoring byMRI. Cell Transplant. 2010;19(12):1573–85.
25. Malosio ML, Esposito A, Poletti A. Improving the procedure for
detection of intrahepatic transplanted islets by magnetic resonance
imaging. Am J Transplant. 2009;9(10):2372–82.
26. Evgenov NV, Medarova Z, Pratt J, et al. In vivo imaging of
immune rejection in transplanted pancreatic islets. Diabetes.
2006;55(9):2419–28.
27. Kriz J, Jirak D, Girman P, et al. Magnetic resonance imaging of
pancreatic islets in tolerance and rejection. Transplantation.
2005;80(11):1596–603.
28. Jiao Y, Peng ZH, Zhang JY, et al. Liposome-mediated transfer can
improve the efficacy of islet labeling with superparamagnetic iron
oxide. Transplant Proc. 2008;40(10):3615–8.
29. Zhang S, He H, Lu W, et al. Tracking intrahepatically transplanted
islets labeled with Feridex-polyethyleneimine complex using a
clinical 3.0-T magnetic resonance imaging scanner. Pancreas.
2009;38(3):293–302.
30. Evgenov NV, Pratt J, Pantazopoulos P, Moore A. Effects of glucose
toxicity and islet purity on in vivo magnetic resonance imaging of
transplanted pancreatic islets. Transplantation. 2008;85(8):1091–8.
31. • Saudek F, D Jirak, P Girman, et al. Magnetic resonance imaging
of pancreatic islets transplanted into the liver in humans.
Transplantation. 2010;90(12):1602–06. This is a pilot study of
SPIO-labeled islet imaging in humans. Islets could be observed in
the majority of subjects. The signal strongly decreased 1 week
after transplantation and remained stable up to 24 weeks, but no
correlation was observed between the MRI signal and the number
of transplanted islets.
32. Medarova Z, Vallabhajosyula P, Tena A, et al. In vivo imaging of
autologous islet grafts in the liver and under the kidney capsule in
non-human primates. Transplantation. 2009;87(11):1659–66.
33. • Crowe LA, F Ris, S Nielles-Vallespin, et al. A novel method for
quantitative monitoring of transplanted islets of langerhans by
positive contrast magnetic resonance imaging. Am J Transplant.
2011;11(6):1158–68. This discusses a new semiautomated quan-
tification method of MRI signal coming from SPIO-labeled islets
that can be translated in humans.
34. Toso C, Vallee JP, Morel P, et al. Clinical magnetic resonance
imaging of pancreatic islet grafts after iron nanoparticle labeling.
Am J Transplant. 2008;8(3):701–6.
35. Juang JH, Wang JJ, Shen CR, et al. Magnetic resonance imaging of
transplanted mouse islets labeled with chitosan-coated superparamag-
netic iron oxide nanoparticles. Transplant Proc. 2010;42(6):2104–8.
36. • Lee N, H Kim, SH Choi, et al. Magnetosome-like ferrimagnetic
iron oxide nanocubes for highly sensitive MRI of single cells and
transplanted pancreatic islets. Proc Natl Acad Sci USA. 2011;108
(7):2662–67. This discusses a new iron particle for pretransplan-
tation islet labeling giving a stronger hyposignal on T2-weighted
sequences than Feridex.
37. Biancone L, Crich SG, Cantaluppi V, et al. Magnetic resonance
imaging of gadolinium-labeled pancreatic islets for experimental
transplantation. NMR Biomed. 2007;20(1):40–8.
38. Barnett BP, Arepally A, Karmarkar PV, et al. Magnetic resonance-
guided, real-time targeted delivery and imaging of magneto-
capsules immunoprotecting pancreatic islet cells. Nat Med.
2007;13(8):986–91.
39. • Barnett BP, J Ruiz-Cabello, P Hota, et al. Fluorocapsules for
improved function, immunoprotection, and visualization of cellular
therapeutics with MR, US, and CT imaging. Radiology. 2011;258
(1):182–91. Describes islet encapsulation with the addition of
perfluorocarbon inside the capsule, acting as a multimodal contrast
agent, detected by MRI, ultrasonography, and CT imaging.
40. Antkowiak PF, Tersey SA, Carter JD, et al. Noninvasive assessment
of pancreatic beta-cell function in vivo with manganese-enhanced
382 Curr Diab Rep (2011) 11:375–383
magnetic resonance imaging. Am J Physiol Endocrinol Metab.
2009;296(3):E573–8.
41. Hathout E, Sowers L, Wang R, et al. In vivo magnetic resonance
imaging of vascularization in islet transplantation. Transpl Int.
2007;20(12):1059–65.
42. Chan NK, Obenaus A, Tan A, et al. Monitoring neovascularization
of intraportal islet grafts by dynamic contrast enhanced magnetic
resonance imaging. Islets. 2009;1(3):249–55.
43. Sakata N, Obenaus A, Chan NK, et al. Correlation between
angiogenesis and islet graft function in diabetic mice: magnetic
resonance imaging assessment. J Hepatobiliary Pancreat Sci.
2010;17(5):692–700.
44. Denis MC, Mahmood U, Benoist C, et al. Imaging inflammation of
the pancreatic islets in type 1 diabetes. Proc Natl Acad Sci USA.
2004;101(34):12634–9.
45. Toso C, Zaidi H, Morel P, et al. Positron-emission tomography
imaging of early events after transplantation of islets of Langerhans.
Transplantation. 2005;79(3):353–5.
46. • Eriksson O, T Eich, A Sundin, et al. Positron emission
tomography in clinical islet transplantation. Am J Transplant.
2009;9(12):2816–24. Using [18F]FDG-prelabeled islets, authors
observed that 25% of the injected radioactivity was lost just after
infusion, suggesting loss of islets during procedure. This technique
can also study the islet distribution in the human liver.
47. Lu Y, Dang H, Middleton B, et al. Noninvasive imaging of islet
grafts using positron-emission tomography. Proc Natl Acad Sci
USA. 2006;103(30):11294–9.
48. Kim SJ, Doudet DJ, Studenov AR, et al. Quantitative micro positron
emission tomography (PET) imaging for the in vivo determination of
pancreatic islet graft survival. Nat Med. 2006;12(12):1423–8.
49. Lu Y, Dang H, Middleton B, et al. Long-term monitoring of
transplanted islets using positron emission tomography. Mol Ther.
2006;14(6):851–6.
50. •• Wu Z, F Kandeel. Radionuclide probes for molecular imaging
of pancreatic beta-cells. Adv Drug Deliv Rev. 2010;62(11):1125–38.
This is a comprehensive review of potential nuclear probes for PET
β-cell imaging.
51. Wild D, Wicki A, Mansi R, et al. Exendin-4-based radio-
pharmaceuticals for glucagonlike peptide-1 receptor PET/CT and
SPECT/CT. J Nucl Med. 2010;51(7):1059–67.
52. • Christ E, D Wild, F Forrer, et al. Glucagon-like peptide-1
receptor imaging for localization of insulinomas. J Clin Endocrinol
Metab. 2009;94(11):4398–405. PET GLP-1 receptor imaging with
[111In]DOTA-exendin-4 probe is effective to diagnose pancreas
insulinoma and could be a potential technique for transplanted islet
imaging.
53. Pattou F, Kerr-Conte J, Wild D. GLP-1-receptor scanning for
imaging of human beta cells transplanted in muscle. N Engl J
Med. 2010;363(13):1289–90.
54. Ris F, Toso C, Morel P, et al. Imaging of islets grafts. Curr Opin
Organ Transplant. 2007;12:659–63.
55. Sweet IR, Cook DL, Lernmark A, et al. Non-invasive imaging of
beta cell mass: a quantitative analysis. Diabetes Technol Ther.
2004;6(5):652–9.
Curr Diab Rep (2011) 11:375–383 383
